Pathogenic and likely pathogenic mutations were distributed over 51 cancer-related genes, including TP53 mutations in 86% of the cases (Table 2); 87%, 91%, 97%, and 67% had pathogenic or likely pathogenic mutations among platinum-sensitive, partially platinum-sensitive, platinum-resistant, and platinum-refractory patients, respectively. Here, TP53 is linked to cancer.